Anders Månsson, Styrelseordförande: Jag har idag nöjet att annonsera att vi nu rekryterat en ny heltidsanställd VD med immunologisk kompetens till CanImGuide. Han heter Carl-Magnus Högerkorp, och tillträder 1 januari. Nuvarande VD Johan Drott har ju sedan i juni varit…Read More
New discoveries in cancer related immunosuppression are paving the way for an entirely new immunotherapeutic strategy.
PRESS RELEASE Lund, Sweden and Naples, Italy – November 28, 2018 New discoveries in cancer related immunosuppression are paving the way for an entirely new immunotherapeutic strategy. Cancer immunotherapy – the treatment approach that utilizes and enhances the power of…Read More
CanImGuide Therapeutics AB, a private biopharmaceutical company based in Lund, Sweden, developing immunology therapeutics, announces that the clinical development of P28R, the company’s lead cancer drug, the first in a new class of immune-modulating drugs, has been initiated in Lund.…Read More
The Nobel Prize in Medicine puts the spotlight on CanImGuide’s focus area Immunology. The Nobel Prize laureates have been awarded for the groundbreaking work in immunonucleology that led to the drugs called checkpoint inhibitors, which is used today successfully. Despite…Read More